Management of Very Labile Blood Pressure in End‑Stage Renal Disease Patients Requiring Vasopressors

Vasopressor Selection and Titration

Norepinephrine should be used as the first‑line vasopressor, targeting a mean arterial pressure (MAP) of ≥ 65 mm Hg, while volume status is optimized through dialysis rather than aggressive fluid removal. Strong evidence supports this approach in critically ill patients with renal disease. 1, 2
Add vasopressin (up to 0.03 U/min) to norepinephrine when additional blood‑pressure support is needed or to reduce the norepinephrine dose requirement. 1, 2
Introduce epinephrine as a third agent only if norepinephrine + vasopressin fail to maintain adequate MAP. 1, 2
Avoid low‑dose dopamine; it does not confer renal protection and should not be used for that purpose. 1, 2

Maintain MAP ≥ 65 mm Hg during vasopressor‑dependent states to preserve organ perfusion in ESRD patients whose renal autoregulation is often lost. 1

During hypotensive episodes, reduce ultrafiltration rates and extend dialysis treatment time (rather than increasing session frequency) to achieve gentler fluid removal. 3
During hypertensive episodes, modestly lower dry‑weight targets but avoid aggressive ultrafiltration while the patient is hemodynamically unstable. 3
Consider switching chronically hypotensive patients to peritoneal dialysis when they cannot tolerate intermittent volume shifts. 3

Increase treatment duration to keep the ultrafiltration rate < 10–13 mL/kg/h. 3
Dialysate sodium concentration may be adjusted; lower sodium reduces interdialytic weight gain but can worsen hypotension, so decisions should be individualized. 3
Use cooler dialysate temperatures to enhance hemodynamic stability. 3

Maximize peritoneal or residual urinary ultrafiltration to achieve euvolemia. 3
Increase hemodialysis frequency or duration (home or nocturnal schedules) when volume control alone is insufficient. 3
Restrict dietary sodium intake to < 2 g/day. 4

ACE inhibitors or ARBs are first‑line agents for hypertension in ESRD, offering cardioprotective benefits beyond blood‑pressure reduction. 5, 6
Use extreme caution with ACE inhibitors/ARBs during acute vasopressor‑dependent states; they may precipitate acute renal failure in volume‑depleted or hypotensive patients. 7
Beta‑blockers (e.g., carvedilol, metoprolol succinate, bisoprolol) are reasonable first‑line alternatives, especially in patients with heart failure or coronary disease. 8

Employ standardized office blood‑pressure measurement with automated oscillometric devices. 4
Complement office readings with home or ambulatory blood‑pressure monitoring for a more complete assessment. 4
Place an arterial catheter for continuous blood‑pressure monitoring in all patients receiving vasopressors. 1, 2

Do not aggressively lower blood pressure during acute vasopressor requirement; maintain MAP ≥ 65 mm Hg. 1
Do not use aggressive ultrafiltration to control blood pressure in unstable patients, as it worsens hemodynamic instability. 3
Temporarily discontinue ACE inhibitors/ARBs during acute hypotensive episodes until hemodynamics stabilize. 7
Reserve phenylephrine for specific indications (e.g., norepinephrine‑induced arrhythmias) and do not use it as a first‑line vasopressor. 1

Crystalloids are the preferred initial fluid for resuscitation when volume depletion contributes to hypotension. 1, 2
Albumin may be added when large volumes of crystalloids are required to avoid excessive fluid load. 1, 2
Hydroxyethyl starches are contraindicated because they increase harm. 1, 2
Continue fluid administration guided by dynamic (pulse‑pressure variation, stroke‑volume variation) or static (arterial pressure, heart rate) hemodynamic variables until improvement is observed. 1, 2